Alnylam Pharmaceuticals

Phase A — Understand the business

Lens 1 · Company Overview

Alnylam is the world's leading RNA interference (RNAi) therapeutics company — it silences disease-causing genes by delivering small interfering RNA (siRNA) that degrades a specific messenger RNA before it makes a harmful protein. After two decades of platform-building and accumulated losses, the company achieved profitability for the first time in 2025. The model is now a real commercial P&L, not a pipeline-only story — which is why this runs as an operating battery.

What it sells (four wholly-owned commercial products + two partner-marketed):

• AMVUTTRA (vutrisiran) — the engine. A subcutaneous siRNA dosed once every three months that knocks down transthyretin (TTR) for ATTR amyloidosis. Originally approved for the polyneuropathy form (hATTR-PN), it won the far larger ATTR cardiomyopathy (ATTR-CM) indication in the U.S. in March 2025. That single label expansion is the whole inflection.
• ONPATTRO (patisiran) — the older IV-infused TTR silencer; now in structural decline as Amvuttra cannibalizes it (same target, far more convenient dosing).
• GIVLAARI (givosiran) — acute hepatic porphyria. Small, steady grower.
• OXLUMO (lumasiran) — primary hyperoxaluria type 1. Small, steady grower.
• Partner-marketed (royalty/collaboration to Alnylam): Leqvio (inclisiran) — twice-yearly cholesterol-lowering siRNA, marketed by Novartis; Qfitlia (fitusiran) — hemophilia, marketed by Sanofi.

Customers / channel: specialty pharma distribution to physicians treating rare and (now) cardiac-amyloid patients; revenue is overwhelmingly U.S. (see Lens 4). The product is buy-and-bill / specialty-pharmacy, not retail.

Contract structure — the load-bearing economic fact: Amvuttra carries a tiered royalty owed to Sanofi on global net sales (a legacy of the patisiran/vutrisiran TTR license): 15% on the first $150M, escalating through 17.5% / 20% / 25%, and 30% on annual sales above $1.5B. As Amvuttra scales past $1.5B/yr, an increasing slice of every incremental dollar leaks to Sanofi — this is the central margin headwind and the reason management keeps pointing at nucresiran (next-gen TTR, zero Sanofi royalty) as the gross-margin fix.

Strategy: "Alnylam 2030" (launched Jan 2026) — the public five-year aspiration: expand to 10 tissue types and >40 clinical programs, deliver ≥2 new non-TTR blockbusters, invest ~30% of revenue in non-GAAP R&D, hit 25%+ total-revenue CAGR, and reach ~30% non-GAAP operating margin by year-end 2030.

Lens 2 · Supply Chain

RNAi therapeutics are chemically synthesized oligonucleotides — the "supply chain" is manufacturing + conjugation chemistry + cold-ish specialty distribution, not a multi-tier hardware BOM. Mapping upstream → company → patient:

• Upstream inputs: synthetic nucleotide building blocks (phosphoramidites), the GalNAc conjugation chemistry that targets siRNA to the liver (Alnylam's proprietary delivery platform — the reason most of its drugs are simple subcutaneous shots), lipid-nanoparticle components (legacy, for the older IV Onpattro). Specialty CDMO/oligo suppliers are the named chokepoint class; Alnylam runs its own Norton, MA manufacturing plus contract capacity. PP&E on the balance sheet is $518.3M — a real manufacturing footprint, not virtual.
• The company: discovers (RNAi platform IP), develops (clinical), manufactures (in-house + CDMO), and commercializes directly in the U.S. and EU.
• Downstream / end customer: specialty distributors → treating physicians (cardiologists now, not just neurologists, post ATTR-CM) → patients. Inventory is tiny relative to revenue ($84.0M ) — consistent with a high-value, low-volume specialty drug.
• Partner "buyers" of the platform: Novartis (Leqvio), Sanofi (Qfitlia + the Amvuttra royalty counterparty), Roche/Genentech (zilebesiran hypertension), Regeneron (C5 complement / CNS+eye collaboration). These are simultaneously customers (collaboration revenue), validators, and — in Sanofi's case — a royalty claimant on the core franchise.

Chokepoints: oligonucleotide manufacturing scale-up (industry-wide constraint as siRNA volumes grow); single-source API steps; and the Sanofi royalty as an economic chokepoint on the flagship.

Lens 3 · Competitive Advantages (moats)

Alnylam's moat is the strongest in its sub-sector, and it is multi-layered:

1. Platform + IP estate (the deepest moat). Alnylam holds the foundational RNAi/GalNAc-delivery patent estate and ~20 years of chemistry know-how. siRNA is a modality, not one drug — every new target is a new shot on goal off the same platform. This is what makes the "10 tissues / 40 programs" 2030 goal credible rather than aspirational hand-waving. The risk: foundational patents have finite life (patent-cliff dynamics apply to platforms too).
2. Mechanism advantage vs. oral competitors in TTR. Amvuttra silences TTR production (siRNA), driving deep, durable knockdown with a once-every-3-months subcutaneous shot. The orals — Pfizer's tafamidis (stabilizer) and BridgeBio's Attruby/acoramidis (stabilizer) — stabilize the protein but don't reduce it, and require daily dosing. Knockdown vs. stabilization is the clinical debate; convenience (q3-month injection vs. daily pill) cuts both ways.
3. Switching costs / first-in-class durability in rare indications (Givlaari, Oxlumo) — these are effectively monopolies in ultra-rare diseases with no competition incentive.
4. Scale as a moat now. Crossing into profitability means Alnylam can self-fund the 40-program pipeline from product cash flow — a structural advantage over pre-revenue RNAi peers (Arrowhead, Ionis) who must dilute or partner to fund pipelines.

Bargaining power: strong over patients/payers in rare disease (no alternative); weaker in ATTR-CM where three franchises now compete and payers gain leverage; and structurally weak vs. Sanofi, who holds an escalating royalty on the flagship that Alnylam cannot renegotiate away (only out-innovate via nucresiran).

---

Phase B — Measure performance

Lens 4 · Segments (product + geography)

Alnylam reports a single operating segment but discloses revenue by product and by geography. The story is total TTR-franchise concentration and U.S. concentration.

Q1 2026 net product revenue by product (vs. Q1 2025), $000s:

Geography (Amvuttra, Q1 2026): U.S. $702.6M (+255%), Europe $113.3M (+41%), RoW $74.1M (+132%). The U.S. is the entire growth engine — the ATTR-CM launch is a U.S. cardiology phenomenon. This is geographic and product concentration stacked.

FY2025 by product, $000s: AMVUTTRA 2,313,836 (+138%); ONPATTRO 172,789 (−32%); Total TTR 2,486,625 (+103%); plus Rare (~$500M) → Total net product revenue $2,986,549 (+81%).

Trend & cause — accelerating, single-driver: TTR went from 83% of FY2025 product revenue to 88% in Q1 2026, and Amvuttra alone is ~86% of Q1 product revenue. The Onpattro decline is intentional cannibalization — same target, Amvuttra is the better dosing form. Concentration is the price of the inflection: one drug, one indication (ATTR-CM), one geography (U.S.) is carrying the company. Total revenue (incl. collaborations + royalty): FY2025 $3,713.9M (+65%), Q1 2026 $1,167.2M (+96%).

Lens 5 · Earnings Result (latest print — Q1 2026)

The Q1 2026 print (reported 2026-04-30) is the cleanest evidence of the inflection.

• Revenue: Total $1,167.2M, +96% YoY; net product $1,036.1M (+121%) — first-ever $1B+ product-revenue quarter. Beat consensus of ~$1.12B by ~4%.
• Profit: Net income $206.0M vs a −$18.3M loss in Q1 2025. Income from operations $268.6M vs $18.1M.
• EPS: $1.99, crushing the ~$0.91 consensus (+119% beat).
• Margins: Product gross margin ~80% (COGS $207.5M / product rev $1,036.1M), down from ~85% a year prior — the Sanofi royalty mix-shift biting as Amvuttra scales into higher royalty tiers. R&D $364.9M (+38%), SG&A $322.6M (+34%) — investing behind the launch but operating leverage is now visible (revenue +96% vs opex +56%).
• Balance sheet: Cash + marketable securities $3,009.2M ($1,710.8M cash + $1,298.4M securities); convertible debt $1,009.4M; plus $1,697.2M of "liabilities related to sale of future royalties and development funding" (royalty-monetization financing — see Lens 10). Accounts receivable $884.0M (up from $777.6M) — growing slightly slower than revenue, which is healthy. Inventory $84.0M.
• Cash flow: Operating cash flow +$70.5M (vs −$120.3M prior year) — the company now self-funds.
• Guidance (the headline): FY2026 TTR product revenue $4.4-4.7B, total product revenue $4.9-5.3B (~+71% at midpoint vs 2025); collaboration + royalty $400-500M.
• Market reaction: muted — shares +1.26% to ~$305 premarket. A +119% EPS beat that barely moved the stock signals the growth is already heavily priced in (see Lens 7) — the market reacts to durability and competition, not the print.

Unusual vs. its own history: the swing from chronic losses (accumulated deficit $6.70B at YE2025) to a $206M quarterly profit in ~12 months is the standout. Nothing in the print looks aggressive; the SBC and royalty-interest non-cash items are large but disclosed (Lens 10).

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts/ empty) — web-grounded. Management tone across the last several quarters has shifted from "approaching profitability / launch execution" to "durable TTR leadership + harvest the cash to fund the pipeline.". The recurring phrases now: "Alnylam 2030," "durable leadership in TTR," "financial discipline and agility," "high-yielding pipeline with blockbuster opportunities." CEO Yvonne Greenstreet used the 2025 results + Alnylam 2030 launch to reframe the company from emerging biotech to sustainably profitable RNAi leader. What they've stopped saying: any hedging about reaching profitability — that question is answered. The new contested ground management proactively addresses: ATTR-CM competitive positioning vs. the orals, and the nucresiran margin story. Sentiment: confident, execution-focused, slightly defensive on competition — appropriate for a company whose growth is now a "can they hold share" question, not a "will it work" question.

Lens 7 · Comps

Alnylam is a growth-at-scale RNAi leader — its multiples sit far above pre-revenue RNAi peers and reflect priced-in hyper-growth. Provenance-critical: multiples are `` with date, or n/a.

Read: the direct RNAi comps (Ionis, Arrowhead) are not valuation comps — they're pre-scale; Arrowhead's first drug did $57M over nine months vs Alnylam's $1B in one quarter. Alnylam has no peer at its commercial stage in RNAi — it is the category. The right valuation frame is "profitable specialty/rare-disease grower priced for ~25%+ CAGR," i.e. a Vertex-like multiple structure. Forward P/E ~70 and P/S ~14.6 are not cheap — they bake in flawless execution of the +71% guide and continued ATTR-CM dominance. Specific peer multiples were not sourced this run and are marked n/a rather than fabricated. 5-yr average ROE is not meaningful — Alnylam was loss-making for most of the period (accumulated deficit $6.70B; positive ROE only emerged 2025).

Lens 8 · Stock-Price Catalysts (>5% moves, pattern)

The market reacts to TTR/ATTR-CM datapoints and competitive news, far more than to GAAP prints:

• HELIOS-B positive readout + ATTR-CM approval (2024→March 2025) — the foundational re-rate; turned Amvuttra from a niche PN drug into a multi-billion cardiac franchise.
• Quarterly TTR revenue beats/misses — the stock trades on Amvuttra trajectory. Note: Q4 2025 was framed as "Amvuttra ATTR revenue disappoints" even as the company turned profitable — the tape cares about the growth slope, not the profit milestone. Q1 2026's $1B quarter was a beat but barely moved the stock (already priced).
• Competitive prints — Pfizer reporting U.S. ATTR sales declines, BridgeBio's stock plunging ~15% on a European tafamidis patent revocation — ATTR-market structure news moves all three names.
• Pipeline binary events — ZENITH (zilebesiran CVOT) and TRITON (nucresiran) initiations; mivelsiran Alzheimer's/CAA data.

Pattern: ALNY is a single-franchise momentum stock dressed as a diversified biotech — the dominant variable is the Amvuttra growth slope and ATTR-CM share, not earnings quality. A growth slope that decelerates (even while still growing) is the documented downside trigger.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO: Dr. Yvonne Greenstreet (CEO since Jan 2022; President/COO 2020-21, COO 2016-19). Track record: she ran the company through the profitability inflection she'd promised — the single most credibility-building thing a biotech CEO can do (deliver the "path to profitability" rather than perpetually push it out). Prior: SVP/Head of Medicines Development at Pfizer; 18 years at GlaxoSmithKline (SVP, Chief Strategy Officer for R&D). A development/strategy operator, not a founder-scientist — fitting for a company transitioning from discovery org to commercial machine.
• Tenure & skin in the game: ~4 years as CEO, ~10 years at the company. Insider-ownership data not pulled this run (insider-transactions.csv absent) — n/a; worth pulling before a position.
• Capital allocation: the watch-era record is (1) disciplined R&D scaling (~30% of revenue, by design), (2) royalty monetization (selling future royalty streams for upfront cash — efficient non-dilutive financing, but it front-loads value and adds the $1.7B royalty-liability line, Lens 10), and (3) convertible-debt management (2027/2028 notes, capped calls, induced conversions) — sophisticated but complex, slightly dilutive. No buybacks (appropriate — reinvesting at high returns). ROE/ROIC turned positive only in 2025; the real capital-allocation test (deploying the new product cash flow into the 40-program pipeline) is ahead, not behind.
• Red flags: none material in governance terms. The Sanofi royalty isn't a related-party red flag — it's a legacy license term. Convertible-note/capped-call complexity is a modeling nuisance, not a governance issue. 23 holders of record (institutional-dominated; benign).
• Archetype: professional manager executing a founder-built platform (Alnylam's science traces to the original RNAi founders/MIT-era IP). Right archetype for the commercialization-and-scale stage.

Lens 10 · Forensic Red Flags

SEC enforcement: None. Zero SEC Litigation Releases and zero AAERs naming Alnylam in 2021-06-20 → 2026-06-20.

Item 3 / Legal Matters (10-K Note 13): the disclosure is generic industry boilerplate — patent litigation, product liability, government investigations described as categories common to the industry, with no specific material pending matter accrued or quantified. For a 20-year-old RNAi pioneer this is notably clean (no marquee patent war disclosed as material as of the 10-K).

Non-SEC enforcement (web): no material FTC/DOJ/FDA enforcement actions, consent decrees, or settlements surfaced for Alnylam in the search window.

Accounting risks to watch (label every figure):

1. Royalty-monetization liabilities — the biggest "read-the-footnotes" item. $1,697.2M of "liabilities related to the sale of future royalties and development funding" sits on the balance sheet, and non-cash interest on it was $66.2M in Q1 alone. This is legitimate, disclosed financing (selling future Leqvio/other royalty streams for upfront cash), but it (a) front-loads revenue/cash into the past, (b) creates a large non-cash interest drag below the line, and (c) makes "net debt" understate the true claim on future cash. Not a red flag, but a complexity that flatters near-term liquidity and burdens future GAAP interest.
2. Stock-based comp: $70.2M in Q1 (~34% of net income). Standard for biotech, but non-GAAP "operating margin" targets (the Alnylam 2030 30% goal) exclude SBC — watch the GAAP-vs-non-GAAP gap as the margin story is told.
3. Convertible-note / induced-conversion noise: multiple 2027/2028 note transactions, capped calls, $39.1M inducement expense on a 2027-note repurchase. Below-the-line, non-operating, but it muddies GAAP net income comparability quarter to quarter.
4. Gross-margin trajectory: the ~85%→80% product-margin slide is economically real (Sanofi royalty tiering), not an accounting artifact — but it means revenue growth overstates gross-profit growth. The bull case requires nucresiran (royalty-free) to reverse it.
5. Receivables vs. revenue: AR $884.0M growing slower than revenue — clean, no channel-stuffing signal.

Verdict on the books: clean accounting, no enforcement history, conservative receivables. The only forensic homework is the royalty-liability footnote and the GAAP-vs-non-GAAP margin framing — disclosure quality is good; the complexity is real.

No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Note 13 / Item 3 as of 2026-06-20.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (EPS, next three fiscal years: FY2026E / FY2027E / FY2028E)

Built bottom-up from FY2025 actuals + FY2026 company guidance. Every output line is `` with the arithmetic shown; no forecast.ts logged (watchlist breadth rule).

Anchors: FY2025 GAAP diluted EPS $2.39; FY2025 net income $313.7M; FY2025 total product revenue $2,986.5M; FY2026 guidance: total product revenue $4.9-5.3B (~$5.1B mid), TTR $4.4-4.7B, collab+royalty $400-500M. Shares ~133.5M.

• FY2026 base: total revenue ~$5.6B (product $5.1B mid + collab/royalty ~$0.45B). Q1 2026 already did $1.99 EPS / $206M net income on $1.17B revenue; annualizing the demonstrated margin at scale (op income ~23% of revenue, modest tax) onto ~$5.6B implies net income ~$0.7-0.8B → EPS ~$5.20-6.00. The guide is +71% revenue; operating leverage (revenue growing faster than opex, as Q1 showed) drives EPS up faster than revenue.
• FY2027/2028 base: apply the Alnylam-2030 25%+ revenue CAGR with continued operating leverage toward the ~30% non-GAAP operating-margin target; partially offset by the Sanofi royalty drag deepening as Amvuttra clears the $1.5B/30% tier — until nucresiran (royalty-free, PN launch ~2028 / CM ~2030) starts to relieve it. Range widens with competitive and pipeline uncertainty.
• Bull: ATTR-CM share gains beat the guide, zilebesiran (hypertension, ~11,000-patient ZENITH CVOT) and mivelsiran (Alzheimer's/CAA) de-risk → multiple re-rates on a second growth leg.
• Bear: oral competition (acoramidis, generic tafamidis from 2026) caps Amvuttra share / forces price; margin stays pinned by the royalty; pipeline readouts disappoint → growth decelerates to ~15-20% and the ~70x multiple compresses hard.

Key sensitivity: the model is not EPS-fragile in FY2026 (guidance + Q1 run-rate de-risk it) — it is multiple-fragile. At ~70x forward earnings, the EPS could grow 30%+ and the stock still fall if the growth-durability narrative cracks.

rNPV note (pipeline overlay): the three pipeline binaries that matter most — nucresiran (the margin fix + TTR-franchise extension), zilebesiran (hypertension, a potential mega-market second leg with Roche), mivelsiran (Alzheimer's/CAA, high-risk/high-reward CNS shot) — are call options on top of the TTR base. Formal rNPV not computed this run (peak-sales × PoS inputs not sourced); flagged as the highest-value modeling work before sizing a long-dated position.

Lens 12 · Bull vs Bear

Bull case. Alnylam is the RNAi platform company and the first to prove the modality scales to a real, profitable, multi-billion-dollar P&L — a structural milestone the pre-revenue peers (Arrowhead at $57M, Ionis pre-solo-launch) are years from. The TTR franchise is inflecting at +71% guided off a U.S. ATTR-CM launch where Amvuttra's mechanism (silence, q3-month shot) is differentiated against daily-pill stabilizers. Profitability flips the company from dilution-dependent to self-funding a 40-program pipeline — and that pipeline carries genuine second-leg optionality (zilebesiran in hypertension is a potential mass-market drug with Roche footing the CVOT bill; nucresiran both extends TTR leadership and fixes the gross margin by ditching the Sanofi royalty). Management did exactly what it said on profitability — earned credibility for the Alnylam 2030 plan. Consensus is Strong Buy, ~$504 average target vs ~$305-327 spot — the Street sees ~50%+ upside.

Bear case (permanent-impairment risks). (1) The whole company is one drug, one indication, one country — Amvuttra ATTR-CM in the U.S. is ~86% of product revenue. Anything that caps that — oral competition (acoramidis ramping, generic tafamidis from 2026 pressuring the entire ATTR price umbrella), a safety signal, or simply slower-than-guided uptake — hits the core, not a wing. (2) The Sanofi royalty structurally caps margin on the flagship (30% above $1.5B), and the fix (nucresiran) is years and Phase-3 risk away. (3) Valuation is the bear's strongest card: ~70x forward earnings / ~14.6x sales prices flawless execution; a deceleration from +71% to +20% growth — still excellent — could halve the multiple. Pre-mortem (18 months out, thesis broke): Amvuttra ATTR-CM net revenue grew but missed the guide as orals took more new-patient share than modeled and payers used three-way competition to force net price down; the +71% guide became +45%; the ~70x multiple compressed to ~35x; a pipeline readout (zilebesiran or mivelsiran) disappointed, removing the "second leg" call option — and the stock fell 30-40% on growth that was still, in absolute terms, very good.

Are multiples too high? For the base case, ~70x forward is rich but defensible if 25%+ CAGR holds for years and a second leg emerges. For the bear case it is clearly too high. The multiple, not the earnings, is the risk.

Contrarian view (what the market may be refusing to see): the bull consensus ($504 PT, Strong Buy) may be underweighting how good the orals' convenience is in a chronic cardiac population, and overweighting the second-leg pipeline (zilebesiran's CVOT is a multi-year, high-bar readout; CNS RNAi is unproven). Conversely, the bears may be underestimating the durability of siRNA's mechanistic edge as long-term ATTR-CM outcome data accrues. The honest read: consensus is priced for the bull and the stock already sits well below its own targets — meaning the market is quietly hedging the durability question even as analysts stay bullish.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Revenue concentration is extreme and singular. ~86% of product revenue is Amvuttra; Amvuttra is ~77% U.S.; the U.S. growth is one indication (ATTR-CM) launched 15 months ago. This is not a diversified biotech — it's a single-product launch stock. If new-patient share in ATTR-CM shifts even modestly toward the orals, the entire growth story slows.
• The moat is weaker than bulls think in TTR specifically. Yes, siRNA silences vs. stabilizes — but patients and physicians often prefer a daily oral to a quarterly injection, and tafamidis built a $5B+ franchise as a stabilizer. The mechanism debate is not settled in Alnylam's favor; it's a marketing/convenience war as much as a science war.
• The most dangerous competitor bulls underestimate: generic tafamidis (2026) + BridgeBio's Attruby, not just the branded incumbents. A generic stabilizer flooding the ATTR price umbrella could force Amvuttra's net price down even if its volume holds — and Alnylam's margin is already royalty-capped, so net-price compression hits an already-pressured gross margin.
• Capital-allocation / accounting nuance: royalty monetization ($1.7B liability, $66M/qtr non-cash interest) and serial convertible-note engineering (capped calls, $39M induced-conversion charge) mean GAAP net income is noisier and the balance sheet more encumbered than "net cash ~$2B" implies. Not fraud — but the clean-looking liquidity is partly financed by selling the future.
• Assumptions that must hold for ~$305-327: +71% FY2026 revenue delivered, ATTR-CM share held against three-way oral competition, margin not collapsing before nucresiran, and at least one pipeline second leg de-risking. That's a lot of "and."
• If growth disappoints 20-30%: at ~70x forward, the multiple compression alone implies 30-50% downside even with still-strong absolute growth — the asymmetry is unfavorable at this price.
• Single scenario that permanently impairs: a CV-outcomes or safety surprise in ATTR-CM that reframes the silence-vs-stabilize debate against siRNA, combined with generic-tafamidis price destruction — that would cap the flagship permanently and leave a $37-43B company resting on a royalty-capped, price-pressured single drug. Plausibility: moderate (no current safety signal; but competitive price pressure from 2026 generics is near-certain).

Lens 14 · Management Questions (ordered by information value)

1. ATTR-CM new-patient share: what % of newly-diagnosed ATTR-CM patients are starting Amvuttra vs. the orals (tafamidis, acoramidis), and how has that trended the last three quarters?
2. With generic tafamidis entering in 2026, what is your assumed impact on Amvuttra's net price (not list) through 2027, and is the FY2026 guide robust to it?
3. Nucresiran timing and the margin math: what gross-margin improvement do you model when nucresiran (royalty-free) substitutes for Amvuttra, and what's the realistic PN/CM launch window?
4. Quantify the Sanofi royalty drag: at the FY2026 revenue mid-point, how many margin points does the Amvuttra royalty cost you, and where does it peak?
5. ZENITH (zilebesiran): what interim looks exist, what's the realistic readout timeline on an ~11,000-patient CVOT, and what efficacy bar de-risks a hypertension launch?
6. How durable is Amvuttra's q3-month dosing advantage if a competitor brings a less-frequent oral or a longer-acting agent?
7. Mivelsiran (Alzheimer's/CAA): how do you frame the probability of success for an RNAi approach in CNS, and what near-term data changes that view?
8. Capital allocation: with the company now self-funding, what's the threshold for external BD/M&A vs. internal pipeline, and would you do a transformative deal?
9. Walk through the royalty-monetization liabilities — how much future royalty have you sold, what's the remaining non-cash interest runway, and why is this preferable to equity/straight debt?
10. Onpattro: do you actively sunset it, and how much of the TTR "growth" is conversion from Onpattro vs. genuinely new patients?
11. Insider ownership / alignment: how is management/board incentivized on the Alnylam 2030 non-GAAP-operating-margin and CAGR targets specifically?
12. Ex-U.S. expansion: ATTR-CM is overwhelmingly U.S. today — what's the realistic Europe/RoW ramp and reimbursement timeline?
13. Convertible-note strategy: what's the plan for the 2027/2028 notes, and how much dilution/cash should we model on conversion or refinancing?
14. What single competitive or clinical development would most threaten the Alnylam 2030 plan, and how are you hedging it?
15. As GAAP turns durably positive, when do you expect to provide GAAP (not just non-GAAP) operating-margin guidance, given SBC and royalty-interest are large?

---